Shimizu T, Souma S, Nagakura N, Masuzawa T, Iwamoto Y, Yanagihara Y
Department of Microbiology, School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Int Arch Allergy Immunol. 1992;98(4):392-7. doi: 10.1159/000236216.
Three cell lines producing monoclonal antibodies, Az-1 (IgG1), Az-2 (IgG1) and Az-3 (IgM) against aztreonam were established. The epitopes and the cross-reactions of the antibodies with various beta-lactams, which were conjugated with human serum albumin (HSA), were examined by enzyme-linked immunosorbent assay (ELISA) and ELISA inhibition test. In ELISA, Az-1 and Az-2 reacted only with aztreonam and ceftazidime, which have the same acyl side chain. Furthermore, Az-2 showed a strong cross-reaction with carumonam. In the ELISA inhibition test, Az-1 and Az-2 were inhibited from binding to aztreonam-HSA by aztreonam, ceftazidime, aztreonam hydrolysate, aztreonam-epsilon-amino-n-caproic acid (EACA) and ceftazidime-EACA. Az-2 was also inhibited with carumonam. From the above results, it seems that Az-1 can recognize only the degraded structure of monobactam nucleus, and Az-2 can recognize the degraded nucleus moiety and the acyl side chain. On the other hand, Az-3 displayed broad cross-reaction to various beta-lactams in ELISA. Furthermore, the MAb showed no inhibitory reaction with various beta-lactams except aztreonam- and ceftazidime-EACA conjugates in the ELISA inhibition test, suggesting that Az-3 recognize a new antigenic determinant (NAD), which is formed by the conjugation of beta-lactam and carrier protein. The above results indicate that antibodies can recognize at least three epitopes of the degraded product(s) of aztreonam nucleus, acyl side chain and NAD in aztreonam-protein conjugate.
建立了三种产生抗氨曲南单克隆抗体的细胞系,即Az-1(IgG1)、Az-2(IgG1)和Az-3(IgM)。通过酶联免疫吸附测定(ELISA)和ELISA抑制试验,检测了这些抗体与各种与人血清白蛋白(HSA)偶联的β-内酰胺类药物的表位和交叉反应。在ELISA中,Az-1和Az-2仅与具有相同酰基侧链的氨曲南和头孢他啶反应。此外,Az-2与卡芦莫南有强烈的交叉反应。在ELISA抑制试验中,氨曲南、头孢他啶、氨曲南水解产物、氨曲南-ε-氨基-n-己酸(EACA)和头孢他啶-EACA可抑制Az-1和Az-2与氨曲南-HSA的结合。卡芦莫南也可抑制Az-2。根据上述结果,似乎Az-1只能识别单环β-内酰胺核的降解结构,而Az-2能识别降解的核部分和酰基侧链。另一方面,Az-3在ELISA中对各种β-内酰胺类药物表现出广泛的交叉反应。此外,在ELISA抑制试验中,除氨曲南和头孢他啶-EACA偶联物外,该单克隆抗体与各种β-内酰胺类药物均无抑制反应,这表明Az-3识别一种由β-内酰胺与载体蛋白结合形成的新抗原决定簇(NAD)。上述结果表明,抗体可识别氨曲南-蛋白质偶联物中氨曲南核降解产物、酰基侧链和NAD的至少三种表位。